• 1
    Gasque P, Neal JW, Singhrao SK, McGreal EP, Van Dean YDBJ, Morgan BP. Roles of the complement system in human neurodegenerative disorders: pro-inflammatory and tissue remodeling activities. Mol Neurobiol 2002; 25:117.
  • 2
    Morgan BP. The complement system: an overview. Meth Mol Biol 2000; 150:113.
  • 3
    Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344:105866.
  • 4
    Harris CL, Morgan BP. Complement regulatory proteins. London: Academic Press, 1999.
  • 5
    Morgan BP, Harris CL. Complement therapeutics; history and current progress. Mol Immunol 2003; 40:15970.
  • 6
    Hughes BW, De Casillas MLM, Kaminski HJ. Pathophysiology of myasthenia gravis. Semin Neurol 2004; 24:2130.
  • 7
    Newsom-Davis J, Pinching AJ, Vincent A, Wilson SG. Function of circulating antibody to acetylcholine receptor in myasthenia gravis: investigation by plasma exchange. Neurology 1978; 28:26672.
  • 8
    De Baets M, Stassen MHW. The role of antibodies in myasthenia gravis. J Neurol Sci 2002; 202:511.
  • 9
    Nastuk WL, Plescia OJ, Osserman KE. Changes in serum complement activity in patients with myasthenia gravis. Proc Soc Exp Biol Med 1960; 105:17784.
  • 10
    Engel AG, Lambert EH, Howard FM. Immune complexes (IgG and C3) at the motoe end-plate in myasthenia gravis: ultrastructural and light microscopic localisation and electrophysiologic correlations. Mayo Clin Proc 1977; 52:26780.
  • 11
    Sahashi K, Engel AG, Lindstrom J, Lambert EH, Lennon VA. Ultrastructural localisation of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis. J Neuropath Exp Neurol 1978; 37:21223.
  • 12
    Sahashi K, Engel AG, Lambert EH, Howard FM. Ultrastructural localisation of the terminal and lytic ninth complment component (C9) at the motor end-plate in myasthenia gravis. J Neuropath Exp Neurol 1980; 39:16072.
  • 13
    Lennon VA, Lambert EH. Myasthenia gravis induced by monoclonal antibodies to acetylcholine receptors. Nature 1980; 285:23840.
  • 14
    Lennon VA, Seybold ME, Lindstrom J, Cochrane C, Ulevitch R. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J Exp Med 1978; 147:97383.
  • 15
    Baalasubramanian S, Harris CL, Donev R et al. CD59a is the primary regulator of membrane attack complex assembly in the mouse. J Immunol 2004; 173:368492.
  • 16
    Miwa T, Sun X, Ohta R, Okada N, Harris CL, Morgan BP, Song WC. Characterization of glycosylphosphatidylinositol-anchored decay accelerating factor (GPI-DAF) and transmembrane DAF gene expression in wild-type and GPI-DAF gene knockout mice using polyclonal and monoclonal antibodies with dual or single specificity. Immunology 2001; 104:20714.
  • 17
    Lin F, Fukuoka Y, Spicer A et al. Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies. Immunology 2001; 104:21525.
  • 18
    Holt DS, Botto M, Bygrave AE, Hanna SM, Walport MJ, Morgan BP. Targeted deletion of the CD59 gene causes spontaneous intravascular haemolysis and haemoglobinuria. Blood 2001; 98:4429.
  • 19
    Suny XJ, Funk CD, Deng CJ, Sahu A, Lambris JD, Song WC. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. Proc Natl Acad Sci USA 1999; 96:62833.
  • 20
    Miwa T, Maldonado MA, Zhou L et al. Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/Ipr mice. Am J Pathol 2002; 161:107786.
  • 21
    Lennon VA, Lambert EH. Monoclonal autoantibodies to acetylcholine receptors: evidence for a dominant idiotype and requirement of complement for pathogenicity. Ann NY Acad Sci 1981; 377:7796.
  • 22
    Piddlesden SJ, Jiang S, Levin JL, Vincent A, Morgan BP. Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. J Neuroimmunol 1996; 71:1737.
  • 23
    Mozrzymas JW, Lorenzon P, Riviera AP, Tedesco F, Ruzzier F. An electrophysiological study of the effects of myasthenia gravis sera and complement on rat isolated muscle fibers. J Neuroimmunol 1993; 45:15562.
  • 24
    Biesecker G, Gomez CM. Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. J Immunol 1989; 142:26549.
  • 25
    Christadoss P. C5 gene influences the development of murine myasthenia gravis. J Immunol 1988; 140:258992.
  • 26
    Tuzun E, Scott BG, Goluszko E, Higgs S, Christadoss P. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J Immunol 2003; 171:384754.
  • 27
    Mead RJ, Neal JW, Griffiths MR et al. Deficiency of the complement regulator CD59a enhances disease severity, demyelination and axonal injury in murine acute experimental allergic encephalomyelitis. Lab Invest 2004; 84:218.
  • 28
    Williams AS, Mizuno M, Richards PJ, Holt DS, Morgan BP. Deletion of the gene encoding CD59a in mice increases disease severity in a murine model of rheumatoid arthritis. Arthritis Rheum 2004; 50:303544.
  • 29
    Turnberg D, Botto M, Warren J, Morgan BP, Walport MJ, Cook HT. CD59a deficiency exacerbates acclerated nephrotoxic nephritis in mice. J Am Soc Nephrol 2003; 14:263642.
  • 30
    Lin F, Salant D, Meyerson H, Emancipator S, Morgan BP, Medof ME. Respective roles of decay-accelerating factor and CD59 in circumventing glomerular injury in acute nephrotoxic nephritis. J Immunol 2004; 172:263642.
  • 31
    Lin F, Kaminski HJ, Conti-Fine BM, Wang W, Richmonds C, Medof ME. Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J Clin Invest 2002; 110:126974.
  • 32
    Rodriguez de Cordoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez Trascasa M, Sanchez-Corral P. The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol 2004; 41:35567.
  • 33
    Nakano S, Engel AG. Myasthenia gravis − quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients. Neurology 1993; 43:116772.
  • 34
    Fleisig AJ, Verrier ED. Pexelizumab − a C5 complement inhibitor for use in both acute myocardial infarction and cardiac surgery with cardiopulmonary bypass. Expt Opin Biol Ther 2005; 5:8339.
  • 35
    Hill A, Ridley SH, Esser D et al. Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy. Blood 2006; 107:21317.